Compare CANG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANG | CRDF |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | 96 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.5M | 114.2M |
| IPO Year | 2018 | 2012 |
| Metric | CANG | CRDF |
|---|---|---|
| Price | $0.29 | $1.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $9.63 |
| AVG Volume (30 Days) | 816.5K | ★ 1.7M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $428.72 | N/A |
| Revenue Next Year | $18.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $0.29 | $1.35 |
| 52 Week High | $5.75 | $4.56 |
| Indicator | CANG | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 30.73 | 48.15 |
| Support Level | N/A | $1.49 |
| Resistance Level | $0.50 | $1.76 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.93 | 37.69 |
Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The operations are divided into two reportable segments (i) Bitcoin Mining Business and (ii) International Automobile Trading Business. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.